The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

A warning from U.S. regulators linking GlaxoSmithKline Plc’s diabetes drug Avandia to rare cases of swelling in the back of the eye is unlikely to have a major impact on sales, analysts said on Friday.

The Food and Drug Administration highlighted the problem in a notice late on Thursday after the drug maker said it had received “very rare” reports of the swelling, known as macular oedema, in patients taking Avandia.

The warning also applies to Avandamet, a combination product containing the same active ingredient, and Avandaryl, which will be available later in January.

Comments are closed.

Of Interest